The Aim of the trial to evaluate the effectiveness of intralesional ciprofloxacin 0.2% solution as a local injection in treating cutaneous leishmaniasis and compare its effect with intralesional sodium stibogluconate (SSG) 10% intravenous solution in cutaneous leishmaniasis as a local injection.
In a randomized parallel groups clinical trial, patients were divided into two groups based on therapeutic regimen: 1) intralesional sodium stibogluconate weekly injection and 2) intralesional ciprofloxacin injection. Each lesion was considered a case in the final analysis. Each lesion will be followed up for 90 days (censor endpoint) or until the lesions are cured.
Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis
Patients who received anti-leishmaniasis treatment locally or systemically for the last month before this study
patients on prolonged corticosteroid therapy.
Al-Mustafa University College
Lead sponsor
Al-Mustansiriyah University
Collaborator